Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2024
0mins
Source: Globenewswire
Increased Sales Guidance: Celularity Inc. has raised its expected net sales for 2024 to between $54 million and $60 million, up from a previous estimate of $50 million to $56 million, driven by strong sales of advanced biomaterial products, including their new Rebound™ product.
Compliance with Nasdaq Requirements: The company has filed its second quarter Form 10-Q, becoming current with its quarterly report filings after addressing non-compliance issues with Nasdaq due to delayed submissions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
